Isofol Medical Secures FDA Pre-IND Meeting for Arfolitixorin

The latest announcement is out from Isofol Medical AB ( (SE:ISOFOL) ).

Isofol Medical AB announced that it has been granted a Pre-IND meeting with the U.S. FDA, a significant step towards submitting an Investigational New Drug application for arfolitixorin. This development is crucial for the company’s plans to conduct clinical trials in the US, aiming to establish arfolitixorin as an effective treatment for metastatic colorectal cancer. The ongoing phase Ib/II study in Germany is assessing the safety and efficacy of arfolitixorin, with plans to expand the study to additional countries.

More about Isofol Medical AB

Isofol Medical AB is a biotechnology company focused on improving the quality of life and prognosis for patients with severe forms of cancer. The company’s primary product, arfolitixorin, is designed to enhance the effectiveness of standard treatments for solid tumors, particularly in colorectal cancer, which is the third most common cancer globally. Isofol Medical AB is publicly traded on Nasdaq Stockholm.

YTD Price Performance: -53.15%

Average Trading Volume: 416,093

Current Market Cap: SEK168M

Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.